Announce Global Licensing Collaboration - Ipca Laboratories Ltd

Code BSE: 524494 NSE: $IPCALAB Ipca Laboratories, Mumbai and Bhami’s Research Laboratory Announce Global Licensing Collaboration for Novel Subcutaneous Biologics Delivery Technology of Multiple Monoclonal Antibodies Ipca is making significant strides in developing in-house capabilities in biosimilars/biologicals, with a specific emphasis on the development and commercialization of anti-cancer and anti-inflammatory monoclonal antibodies. Ipca has established a world class bio-manufacturing facility in Pithampur (MP) and state of the art R&D facility in Mumbai (MH) for its biosimilar development. These efforts are not just a continuation of the existing work, but rather a bold step forward into vital areas of healthcare.